HMGB1 is an endogenous immune adjuvant released by necrotic cells

By P. Rovere-Querini, A. Capobianco, Paola Scaffidi, B. Valentinis, Federica Catalanotti, M. Giazzon, I. Dumitriu, S. Müller, M. Iannacone, C. Traversari and 2 more. EMBO Reports, 2004

622 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Immunology

View Paper: https://www.semanticscholar.org/paper/f6d73b755626985032f949ebf957b720dc0cf321

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. H. Kono
2. K. Rock
3. Michael Lotze
4. Kevin J. Tracey
5. A. Manfredi
6. M. Bianchi
7. Peter Vandenabeele
8. D. Tang

In Immunology

1. H. Kono
2. L. Zitvogel
3. K. Rock
4. Michael Lotze
5. M. Bianchi
6. Kevin J. Tracey
7. A. Manfredi
8. Peter Vandenabeele

Citations in the corpus

• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007, background): “Because HMGB1 is involved in the inflammatory response elicited by dying cell”
• High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity (2007, background): “Certainly, when injected with apoptotic cells in a context similar to vaccination, HMGB1 enhances the immunogenicity of apoptotic cells (62).”
• DAMPs, PAMPs and alarmins: all we need to know about danger (2007, neutral): “dritic cells [20–22].”
• High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart (2008, background): “Here, we demonstrate that (1) HMGB1 is upregulated in cultured neonatal cardiomyocytes by hypoxia and in I/R injury of the heart in vivo; (2) treatment with HMGB1 box A, a functional antagonist of extracellular HMGB1 cytokine activity, and HMGB1 interaction with RAGE significantly protect against I/”
• The inflammatory response to cell death. (2008, background): “In addition, there is also evidence that HMGB1 can also function as a danger signal that could induce DC maturation in vitro and promote antitumor immunity in vivo (108).”
• Hyaluronan Fragments Act as an Endogenous Danger Signal by Engaging TLR21 (2006, background): “Similarly, HMGB1 is emerging as an important inflammatory cytokine released upon necrotic cell death (6).”
• How dying cells alert the immune system to danger (2008, background): “When recombinant HMGB1 was added to immunizations with soluble antigen, it increased antibody responses, and for cellular antigens, it induced protection against tumour challeng”
• High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal (2005, background): “It should also be noted that, in granulocytes, HMGB1 is tightly sequestered in a detergent-insoluble form, which limits its release even under conditions of necrotic cell deat”
• Immunogenic cell death and DAMPs in cancer therapy (2012, background): “These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”